Both teprotumumab and tocilizumab reduce inflammation and thyroid eye disease severity, including among adults who were nonresponders to steroid treatment, according to findings published in Thyroid.
“Medical therapy with teprotumumab and tocilizumab can be considered in patients that have failed steroid therapy for thyroid eye disease,” Marius N. Stan, MD, consultant in endocrinology and chair of the thyroid care group at Mayo Clinic in Rochester, Minnesota, and David Toro-Tobon, MD, assistant professor of medicine in the division of endocrinology, diabetes and metabolism at Mayo